Approximately 75% of a dose of<unk>  is metabolised in the liver. In vitro studies have shown that hepatic CYP2D6 and CYP3A4 are involved in<unk>  metabolism. Within 24 hours of intravenous or oral administration approximately 20% of a dose of<unk>  will be excreted unreacted in the urine. In humans, several metabolic pathways for<unk>  exist. These pathways lead to the formation of a number of different metabolites. One of the metabolites that may result can be formed through the glucuronidation of<unk> . Additionally,<unk>  may undergo oxidation or demethylation at its nitrogen atom, forming two other possible metabolites.<unk>  can undergo demethylation at its oxygen atom, forming an intermediate which can then undergo glucuronidation or sulfate conjugation. Lastly,<unk>  may be oxidized and then reduced before finally undergoing demethylation or oxidation at its nitrogen atom, or demethylation and subsequent glucuronidation at its oxygen atom. Metabolic pathways of<unk>  For Razadyne ER, the once-a-day formulation, CYP2D6 poor metabolizers had drug exposures that were approximately 50% higher than for extensive metabolizers. About 7% of the population has this genetic mutation; however, because the drug is individually titrated to tolerability, no specific dosage adjustment is necessary for this population.
Galantamine
Zonisamide
Tianeptine
Glysobuzole
Phenylpiracetam
Lacosamide
Glybuzole
Heptobarbital